Forxiga helps the kidneys remove glucose and sodium through urine. It contains dapagliflozin, an SGLT2 inhibitor used for eligible adults with type 2 diabetes, heart failure, or chronic kidney disease.
It contains dapagliflozin, an SGLT2 inhibitor used for eligible adults with type 2 diabetes, heart failure, or chronic kidney disease. Its effects can support glucose control, reduce fluid strain on the heart, and help protect kidney function when prescribed for the appropriate indication.
Forxiga is taken by mouth once daily, with or without food. The prescribed dose is decided individually, taking age, other medicines, kidney function, the treated condition, and health conditions into account. The Canadian product monograph and prescriber’s instructions determine the appropriate regimen.
A person taking insulin or a sulfonylurea may need a separate adjustment to that treatment because the combined regimen can increase hypoglycaemia risk. Do not independently reduce insulin to offset increased urination or a lower glucose reading.
Forxiga contains dapagliflozin, an SGLT2 inhibitor supplied as tablets. AstraZeneca developed Forxiga for use in several cardiometabolic conditions. Health Canada-approved use depends on the indication, kidney function, medical history, and the prescriber’s treatment plan. The Canadian product monograph describes dapagliflozin as a medicine that reduces renal glucose reabsorption and increases urinary glucose excretion [1].
Key facts
SGLT2 is a kidney transport protein that normally moves filtered glucose and sodium back into the bloodstream. Dapagliflozin reduces this recovery process. The result is more glucose and sodium leaving the body in urine.
Forxiga is not a replacement for prescribed cardiovascular treatment, blood-glucose monitoring, nutrition planning, or kidney follow-up.
Dapagliflozin inhibits SGLT2 in the kidneys, reducing the reabsorption of glucose and sodium into the blood. As a result, more glucose and sodium are excreted in urine, which can support blood-glucose control and increase urinary fluid loss. These effects may reduce fluid strain on the heart and help protect kidney function when the medicine is prescribed for the appropriate indication.
Forxiga’s role differs according to the condition being treated. The same dapagliflozin mechanism can produce different clinical goals.
Dapagliflozin lowers blood glucose by increasing urinary glucose loss. It can also produce modest fluid and weight changes. The response depends on remaining kidney function, diet, other glucose-lowering medicines, and the person’s starting glucose level.
Forxiga does not cure type 2 diabetes. It forms one part of a treatment plan that may include monitoring, nutrition changes, physical activity, and other medicines.
In suitable adults with heart failure, dapagliflozin can reduce the risk of worsening heart failure and hospitalisation. The benefit is linked to changes in fluid handling, kidney signalling, and heart-kidney workload rather than only to lower blood glucose.
People without diabetes may still receive an SGLT2 inhibitor for an approved heart-failure indication. The treatment decision is based on the type of heart failure, kidney function, blood pressure, fluid status, and the rest of the cardiovascular regimen.
For eligible adults with chronic kidney disease, dapagliflozin may reduce the risk of kidney-function decline and certain cardiovascular outcomes. Kidney monitoring remains necessary because an early change in estimated filtration can occur after treatment begins.
The treatment plan should distinguish an expected laboratory change from acute kidney injury. Low blood pressure, dehydration, infection, and medicines that affect kidney blood flow can alter that assessment.
Forxiga is not suitable for every patient. Assessment before treatment should include the indication, kidney function, blood pressure, hydration status, diabetes regimen, and risk factors for ketoacidosis.
Insulin and sulfonylureas can increase the chance of low blood glucose when combined with Forxiga. Diuretics may intensify fluid loss and low blood pressure. Medicines that affect kidney function may require closer monitoring during dehydration or acute illness. Other glucose-lowering therapies can also require adjustment as blood glucose improves.
Heavy alcohol intake, major surgery, prolonged fasting, and severe infection can increase ketoacidosis risk. Tell the prescribing team about these circumstances before treatment continues.
Monitoring may include:
Forxiga may not be appropriate if you have type 1 diabetes, active ketoacidosis, severe dehydration, repeated vomiting, severe diarrhoea, or kidney function that is unsuitable for the intended treatment. It also requires a clinician-directed plan during pregnancy, planned pregnancy, or breastfeeding. People taking insulin, sulfonylureas, or diuretics need medical review because the combination may increase risks such as low blood glucose, fluid loss, or low blood pressure.
The most relevant adverse effects arise from increased urinary glucose and fluid loss. Genital yeast infections, urinary tract infections, increased urination, thirst, and dehydration are recognised concerns with dapagliflozin.
Genital yeast symptoms often respond better when treated early. Persistent itching, pain, swelling, or unusual discharge should not be ignored. Gentle washing and thorough drying can reduce moisture, though hygiene does not eliminate the possibility of infection.
Contact a healthcare service promptly for painful urination with fever, flank pain, blood in the urine, marked weakness, faintness, or symptoms suggesting significant dehydration. Reduced urine output can signal a more serious fluid or kidney problem.
Diabetic ketoacidosis can occur with only moderately elevated blood glucose. Warning symptoms include nausea, vomiting, abdominal pain, rapid or deep breathing, unusual fatigue, confusion, or a fruity breath odour. These symptoms require urgent medical assessment rather than simply taking more fluids or waiting for the glucose reading to rise.
Severe allergic reactions may cause facial or throat swelling, breathing difficulty, widespread hives, or sudden collapse. Pain, tenderness, redness, swelling, or fever around the genitals or perineum requires urgent assessment because rare but serious soft-tissue infection has been reported with SGLT2 inhibitors.
The Canadian monograph also describes risks related to volume depletion, hypotension, kidney-function changes, infections, and ketoacidosis [2].
Forxiga belongs to the SGLT2 inhibitor class. Other treatments may be selected according to the main condition, kidney function, cardiovascular risk, glucose pattern, risk of hypoglycaemia, and tolerance.
| Treatment category | Examples and clinical role | Main limitation or monitoring point |
|---|---|---|
| SGLT2 inhibitors | Forxiga, Jardiance, and Invokana may support diabetes, heart, or kidney treatment depending on the product and indication | Urinary infections, genital infections, dehydration, and ketoacidosis risk |
| Metformin-based treatment | Metformin, Glucophage SR, and the combination product Xigduo may improve glucose control | Gastrointestinal effects and kidney-function restrictions; Xigduo contains dapagliflozin plus metformin |
| DPP-4 inhibitors or sulfonylureas | Januvia, Onglyza, Vipidia, and gliclazide act through different glucose-lowering pathways | DPP-4 choices have different renal dosing needs; gliclazide can cause hypoglycaemia |
Forxiga and Jardiance are both SGLT2 inhibitors, while Januvia, Onglyza, and Vipidia are DPP-4 inhibitors. Gliclazide is a sulfonylurea that stimulates insulin release and can cause low blood glucose. Glucophage SR is extended-release metformin. Xigduo combines dapagliflozin with metformin, so adding separate Forxiga may duplicate dapagliflozin.
No single option suits every patient. Brand availability and approved indications can vary in Canada, and combination therapy should be prescribed as a complete regimen rather than assembled by duplicating ingredients.
In clinical practice, prescribers often assess Forxiga through three linked questions: what condition is being treated, how well the kidneys are functioning, and whether the patient can maintain hydration.
For type 2 diabetes, the expected benefit is improved glucose handling through urinary glucose loss. For heart failure and chronic kidney disease, the treatment goal may focus more on hospitalisation risk, fluid balance, and preservation of kidney function than on a dramatic glucose change.
A clinician will usually review the full medicine list rather than judging Forxiga alone. Insulin, gliclazide, diuretics, blood-pressure medicines, and drugs affecting kidney function can change the safety profile. The European Medicines Agency describes dapagliflozin’s therapeutic role across diabetes, heart failure, and chronic kidney disease according to the relevant indication and evidence base [3]. The first days or weeks may bring more urination. A modest laboratory change in kidney filtration may occur after initiation, while a larger deterioration with dehydration or illness needs prompt evaluation. These findings require clinical interpretation rather than automatic continuation or discontinuation.
Active diabetic ketoacidosis rules out continued Forxiga treatment and requires urgent medical care. Type 1 diabetes also requires specialist assessment because dapagliflozin can increase ketoacidosis risk in people with insulin deficiency. Health Canada’s Forxiga product information, reviewed in 2025, also supports checking kidney function and treatment suitability before use. The correct decision depends on the clinical indication and current health state.
Do not take extra tablets if glucose, swelling, breathlessness, or kidney results do not improve as expected. The treatment goal differs between type 2 diabetes, heart failure, and chronic kidney disease, so response should be assessed with the relevant measurements. Health Canada guidance available in 2025 supports reviewing kidney function, hydration, adherence, and other medicines when the response is inadequate. Worsening breathlessness, rapid swelling, vomiting, confusion, or severe weakness needs urgent assessment.
Swallow Forxiga tablets with water rather than crushing or chewing them unless a prescriber or pharmacist has given a specific alternative instruction. Health Canada’s Forxiga product monograph from 2025 provides the administration information for the tablet formulation. Splitting can also make it harder to take the intended prescribed amount accurately. If swallowing is difficult, arrange a formulation review instead of altering the tablet routinely.
Forxiga contains dapagliflozin and blocks SGLT2, increasing urinary glucose and sodium excretion. Metformin reduces hepatic glucose production through a different mechanism and does not produce the same osmotic-diuresis effect. The WHO diabetes guidance published in 2023 recognises that medicine selection depends on the person’s glucose pattern, kidney function, cardiovascular disease, adverse-effect risks, and treatment goals. The two medicines may be used together when the combination is prescribed appropriately.
Forxiga may be used long term when the treated condition remains present, the benefit continues, kidney function is suitable, and adverse effects remain manageable. It is not automatically limited to a short course for diabetes, heart failure, or chronic kidney disease. The European Medicines Agency product information from 2025 supports ongoing review of kidney function, fluid status, and treatment response during continued therapy. Temporary withholding may be needed during surgery, prolonged fasting, severe illness, vomiting, or dehydration.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
During the first week I went to the bathroom more often and felt thirsty in the afternoons. That settled into a manageable routine, but I had to stop skipping breakfast because fasting made me feel unwell.
My glucose readings improved over the first month, and I noticed a small change in my weight. The difficult part was a genital yeast infection, which I left for too long before arranging treatment. After that, I recognised the symptoms much earlier.
I did not notice a dramatic day-to-day change, which was frustrating. My cardiology visits focused more on fluid status and kidney tests than on how I felt after each tablet. I became dizzy during a stomach illness and was told to follow a sick-day plan rather than simply keep taking it.
